Abstract
For vectorborne diseases the basic reproduction number ℛ0, a measure of a disease’s epidemic potential, is highly temperature dependent. Recent work characterizing these temperature dependencies has highlighted how climate change may impact geographic disease spread. We extend this prior work by examining how newly emerging diseases, like Zika will be impacted by specific future climate change scenarios in four diverse regions of Brazil, a country that has been profoundly impacted by Zika. We estimated a temperature-dependent ℛ0(T), derived from a compartmental transmission model, characterizing Zika (and, for comparison, dengue) transmission potential. We obtained historical temperature data for the 5-year period 2015–2019 and projections for 2045–2049 by fitting cubic spline interpolations to data from simulated atmospheric data provided by the CMIP-6 project (specifically, generated by the GFDL-ESM4 model), which provides projections under four Shared Socioeconomic Pathways (SSP). These four SSP scenarios correspond to varying levels of climate change severity. We applied this approach to four Brazilian cities (Manaus, Recife, Rio de Janeiro, and São Paulo) that represent diverse climatic regions. Our model predicts that the ℛ0(T) for Zika peaks at 2.7 around 30°C, while for dengue it peaks at 6.8 around 31°C. We find that the epidemic potential of Zika and dengue will increase beyond current levels in Brazil in all of the climate scenarios. For Manaus, we predict that the annual ℛ0 range will increase from 2.1–2.5, to 2.3–2.7, for Recife we project an increase from 0.4–1.9 to 0.6–2.3, for Rio de Janeiro from 0–1.9 to 0–2.3, and for São Paulo from 0–0.3 to 0–0.7. As Zika immunity wanes and temperatures increase, there will be increasing epidemic potential and longer transmission seasons, especially in regions where transmission is currently marginal. Surveillance systems should be implemented and sustained for early detection.
Author summary Rising temperatures through climate change are expected to increase arboviral disease pressure, so understanding the impact of climate change on newly emerging diseases such as Zika is essential to prepare for future outbreaks. However, because disease transmission may be less effective at very high temperatures, it is uncertain whether risk will uniformly increase in different regions. Mathematical modeling is a useful tool for predicting the impact of temperature on arbovirus risk. We used a temperature-dependent infectious disease transmission model to derive a temperature-dependent basic reproduction number. We then used historical temperature data and temperature projections for the years 2045-2049 to forecast Zika risk in four cities in Brazil under various climate change scenarios. We predict an overall increase in arbovirus risk, as well as extended risk seasons in cities that are not currently suitable for year-round spread, such as Rio de Janeiro. We also found little-to-no protective effect of increasing temperatures even in warmer climates like Manaus. Our results indicate that preparation for future Zika outbreaks (and of those of other arboviruses including dengue) should include the implementation of national disease surveillance and early detection systems.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The analysis does not use human subjects data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.